RESUMEN
To determine the benefit of using an H2-receptor antagonist in children with abdominal pain and dyspepsia, 25 such children were enrolled in a double-blind, placebo-controlled trial of famotidine. Global and quantitative pain assessments were done before and after each treatment period. The quantitative assessment was calculated based on the abdominal pain score that was the sum of three components. Based on the global evaluation, there was a clear benefit of famotidine over placebo (68% vs 12%). Using the quantitative assessment, however, the mean improvement of the score using famotidine versus placebo was not statistically significant (3.37+/-3.53 vs 1.66+/-2.7). There was a significant improvement in this score during the first treatment period regardless of medication used (period effect: P = 0.05). A subset of patients with peptic symptoms demonstrated a significant drug effect that outweighed the period effect (drug effect: P = 0.01; period effect: P = 0.02). We conclude that famotidine subjectively improves the symptoms of children with recurrent abdominal pain but not objectively using the derived score. However, famotidine is significantly more effective than placebo among children with peptic symptoms. The use of this simple scoring scale may facilitate selecting those children who will benefit from H2-receptor antagonist therapy.
Asunto(s)
Dolor Abdominal/tratamiento farmacológico , Antiulcerosos/uso terapéutico , Dispepsia/tratamiento farmacológico , Famotidina/uso terapéutico , Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Dimensión del Dolor/métodos , Adolescente , Pruebas Respiratorias , Niño , Preescolar , Método Doble Ciego , Femenino , Infecciones por Helicobacter/diagnóstico , Humanos , Lactosa/análisis , Masculino , Resultado del TratamientoAsunto(s)
Hepatitis C/terapia , Interferón-alfa/uso terapéutico , Niño , Preescolar , Progresión de la Enfermedad , Hepatitis C/complicaciones , Hepatitis C/transmisión , Humanos , Transmisión Vertical de Enfermedad Infecciosa , Cirrosis Hepática/etiología , Fallo Hepático/etiología , Trasplante de Hígado , RecurrenciaRESUMEN
BACKGROUND: To define the onset, pattern, and earliest manifestations of malnutrition related to HIV infection. METHODS: A retrospective cross-sectional analysis of changes in weight and growth in a group of 54 children with perinatally acquired HIV infection was conducted. Eight children had asymptomatic HIV infection, 26 had symptomatic infection, and 20 had symptomatic infection and were referred for nutritional support. RESULTS: We found an early decline in the rate of linear growth with a relative preservation of the weight-for-age. Weight-for-height measurements were preserved until there was advanced HIV-related disease. CONCLUSIONS: This pattern can result in a false impression of adequate nutrition and emphasizes the importance of longitudinal growth data of the child with HIV infection. Evidence of linear growth failure before clinical wasting is apparent is an absolute indication for aggressive nutritional support.
Asunto(s)
Trastornos del Crecimiento/etiología , Síndrome de Emaciación por VIH/complicaciones , Síndrome de Emaciación por VIH/diagnóstico , Adolescente , Niño , Preescolar , Estudios Transversales , Humanos , Lactante , Estudios Retrospectivos , Estadísticas no ParamétricasRESUMEN
BACKGROUND: Liver transplantation is recognized as the appropriate treatment for end-stage liver disease due to chronic active autoimmune hepatitis. While it was initially thought that the disease did not recur after transplant, it is now generally accepted that adult patients may develop recurrent disease, with studies reporting a recurrence rate of < or = 25%. We have noted a higher incidence of recurrent autoimmune hepatitis in our pediatric patients undergoing liver transplant, with a high incidence of associated morbidity. METHODS: We reviewed the records of six children followed up for autoimmune hepatitis who underwent orthotopic liver transplant for complications of end-stage liver disease. RESULTS: Of the six, five developed recurrent autoimmune hepatitis at a mean time of 11.4 months after transplant. The disease was aggressive, leading to cirrhosis and retransplant in three patients, within 1 year of recurrence. A second recurrence of disease occurred in all three retransplanted patients. One patient has received a third liver transplant, one has died, and one patient is asymptomatic on medical therapy. Autoimmune hepatitis recurred in all four patients receiving tacrolimus. CONCLUSION: We conclude that liver transplant for autoimmune hepatitis is likely to be palliative for most pediatric patients. Potent immunosuppressives such as tacrolimus do not protect against the development of recurrent autoimmune hepatitis.